

Technology Advisory Interests Register

Topic: Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6413]

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Mark Corbett	TAC Committee Member	Non-financial professional	I work for the York Technology Assessment Group, who wrote the External Assessment Report for Tafasitamab, though I played no part in the project.	14/04/2026	It was agreed that Mark's declaration would not prevent them from participating in discussions on this appraisal
Elizabeth Thurgar	TAC Committee Member	Financial	In the past 12 months I have worked with Pfizer, a listed comparator company, in an unrelated indication, NSCLC.	14/04/2026	It was agreed that Elizabeth's declaration would not prevent them from participating in discussions on this appraisal
Mike Chambers	TAC Committee Member	Financial	I have attended an advisory panel for Pfizer (possible comparator manufacturer) in an unrelated disease area: prostate cancer.	14/04/2026	It was agreed that Mike's declaration would not prevent them from participating in discussions on this appraisal
Kate Ren	TAC Committee Member	Financial	I provided statistical methodology consultancy service to a possible comparator company Pfizer for an unrelated treatment in an unrelated disease area (Tofacitinib for	20/04/2026	It was agreed that Kate's declaration would not prevent them from

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			Moderate-to-Severe Ulcerative Colitis).		participating in discussions on this appraisal
Satish Venkateshan	TAC Committee Member	Financial	Regeneron is developing Odronextamab CD20xCD3 bispecific antibody. It also has EMA conditional marketing authorisation to treat adult patients with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), who have progressed after at least two prior systemic therapies. I work for Regeneron, pharmaceuticals/biotech company. I also own shares in the company and have stock options.	22/04/2026	It was agreed that Satish's declaration would prevent them from participating in discussions on this appraisal
Dr Mark Bishton	Expert	Direct - financial	• Incyte • £2,310 • Incyte advisory board 14 February 2025 on R2-tafasiamab in follicular lymphoma	01/12/2025	It was agreed that Mark's declaration would not prevent them from providing expert advice to the committee
Professor Andrew Davies	Expert	Direct - financial	I have received payment to chair participate in Incyte hosted clinical advisory board meeting. The indication being assessed in this appraisal was discussed.	01/12/2025	It was agreed that Andrew's declaration would not prevent them from providing expert advice to the committee

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Zoe Drymoussi	Expert	Financial	My organisation has received funding from Incyte for patient education programmes.	26/11/2025	It was agreed that Zoe's declaration would not prevent them from providing expert advice to the committee
Ms Dallas Pounds	Expert	Financial	My organisation has received funding from Incyte for patient support and information.	27/02/2026	It was agreed that Dallas's declaration would not prevent them from providing expert advice to the committee